{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:55:31Z","timestamp":1760100931693},"reference-count":109,"publisher":"Elsevier","isbn-type":[{"value":"9780323399814","type":"print"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1016\/b978-0-323-39981-4.00021-x","type":"book-chapter","created":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T19:26:53Z","timestamp":1475868413000},"page":"393-410","source":"Crossref","is-referenced-by-count":9,"title":["Regulatory Development of Nanotechnology-Based Vaccines"],"prefix":"10.1016","author":[{"given":"H.F.","family":"Florindo","sequence":"first","affiliation":[]},{"given":"J.","family":"Lopes","sequence":"additional","affiliation":[]},{"given":"L.C.","family":"Silva","sequence":"additional","affiliation":[]},{"given":"M.L.","family":"Corvo","sequence":"additional","affiliation":[]},{"given":"M.B.","family":"Martins","sequence":"additional","affiliation":[]},{"given":"R.","family":"Gaspar","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0010","doi-asserted-by":"crossref","first-page":"961","DOI":"10.4161\/hv.21080","article-title":"A vaccinia virus renaissance: new vaccine and immunotherapeutics uses after smallpox erradication","volume":"8","author":"Verardi","year":"2012","journal-title":"Human Vaccin Immunother"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0015","unstructured":"Relev\u00e9 \u00c9pid\u00e9miologique Hebdomadaire\/Section D\u2019hygi\u00e8ne Du Secr\u00e9tariat De La Soci\u00e9t\u00e9 Des Nations\u00a0=\u00a0Weekly Epidemiological Record\/Health Section of the Secretariat of the League of Nations. 2011; 86:301\u201316."},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0020","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/INF.0000000000000930","article-title":"Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine and commonly administered vaccines after co-administration","volume":"35(1)","author":"Gasparini","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0025","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.drudis.2008.04.010","article-title":"Vaccines against intracellular bacterial pathogens","volume":"13","author":"Titball","year":"2008","journal-title":"Drug Discov Today"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0030","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1080\/21645515.2015.1016673","article-title":"Is EU\/EEA population protected from polio?","volume":"11","author":"Nijsten","year":"2015","journal-title":"Human Vaccin Immunother"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0035","doi-asserted-by":"crossref","first-page":"051132","DOI":"10.1103\/PhysRevE.86.051132","article-title":"Impact of committed individuals on vaccination behavior","volume":"86","author":"Liu","year":"2012","journal-title":"Phys Rev E Stat Nonlin Soft Matter Phys"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0040","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.vaccine.2008.01.030","article-title":"TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses","volume":"26","author":"Schlosser","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0045","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1158\/0008-5472.CAN-12-1127","article-title":"Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination","volume":"73","author":"Aarntzen","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0050","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11095-010-0241-4","article-title":"Nanoparticle delivery systems in cancer vaccines","volume":"28","author":"Krishnamachari","year":"2011","journal-title":"Pharm Res"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0055","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.addr.2008.12.009","article-title":"Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles","volume":"61","author":"Malyala","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0060","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jconrel.2013.03.010","article-title":"Immune system targeting by biodegradable nanoparticles for cancer vaccines","volume":"168","author":"Silva","year":"2013","journal-title":"J Control Release"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0065","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0939-6411(00)00062-X","article-title":"Controlled release of drugs from injectable in situ formed biodegradable PLGA microspheres: effect of various formulation variables","volume":"50","author":"Jain","year":"2000","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0070","first-page":"98","article-title":"Cellular uptake of elastic nanoparticles","volume":"10","author":"Yi","year":"2011","journal-title":"Phys Rev Lett"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0075","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0080","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.addr.2007.08.044","article-title":"Protein nanoparticles as drug carriers in clinical medicine","volume":"60","author":"Hawkins","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0085","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1208\/s12248-013-9532-0","article-title":"Different pharmaceutical products need similar terminology","volume":"16","author":"Crommelin","year":"2014","journal-title":"AAPS J"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0090","first-page":"1005","article-title":"Nanotherapeutics in the EU: an overview on current state and future directions","volume":"9","author":"Hafner","year":"2014","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0095","unstructured":"Committee for Medicinal Products for Human Use (CHMP), E.M.A. EMA\/CHMP\/13099\/2013, <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2013\/02\/WC500138390.pdf>; 2013."},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1208\/s12248-013-9533-z","article-title":"How to regulate nonbiological complex drugs (NBCD) and their follow-on versions: points to consider","volume":"16","author":"Schellekens","year":"2014","journal-title":"AAPS J"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/nyas.12403","article-title":"Nanomedicines: addressing the scientific and regulatory gap","volume":"1313","author":"Tinkle","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0110","first-page":"631","article-title":"The nanomedicine revolution: part 3: regulatory and safety challenges","volume":"37","author":"Ventola","year":"2012","journal-title":"P T"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0115","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2174\/156720111795256156","article-title":"Regulating nanomedicine - can the FDA handle it?","volume":"8","author":"Bawa","year":"2011","journal-title":"Curr Drug Deliv"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0120","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1021\/mp200394t","article-title":"Nanomedicine(s) under the microscope","volume":"8","author":"Duncan","year":"2011","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/B978-0-323-39981-4.00021-X_bib0155","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.bbrc.2015.08.023","article-title":"Regulatory aspects on nanomedicines","volume":"468","author":"Sainz","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0125","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejps.2015.04.010","article-title":"The similarity question for biologicals and non-biological complex drugs","volume":"76","author":"Crommelin","year":"2015","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0130","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2217\/nnm.14.189","article-title":"Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars","volume":"10","author":"M\u00fchlebach","year":"2015","journal-title":"Nanomedicine (Lond)"},{"issue":"1","key":"10.1016\/B978-0-323-39981-4.00021-X_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0035-1548911","article-title":"From bioequivalence to biosimilarity: the rise of a novel regulatory framework","volume":"66","author":"Karalis","year":"2015","journal-title":"Drug Res (Stuttg)"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0140","unstructured":"EMA. EMA\/CHMP\/SWP\/620008\/2012, <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2013\/09\/WC500149496.pdf>; 2013."},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0145","unstructured":"FDA. <http:\/\/www.fda.gov\/downloads\/RegulatoryInformation\/Guidances\/UCM401695.pdf>; 2014."},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0150","unstructured":"FDA. <http:\/\/www.fda.gov\/downloads\/Cosmetics\/GuidanceRegulation\/GuidanceDocuments\/UCM300927.pdf>; 2014."},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0160","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2217\/nnm.13.68","article-title":"Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines","volume":"8","author":"Ehmann","year":"2013","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0165","series-title":"Bionanotechnology: a revolution in food, biomedical and health sciences","author":"Bawa","year":"2013"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0170","first-page":"1","article-title":"Nanomedicines for cancer therapy: an update of FDA approved and those under various stages of development","volume":"1","author":"Pillai","year":"2014","journal-title":"SOJ Pharm Pharm Sci"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0175","unstructured":"FDA. <http:\/\/www.fda.gov\/downloads\/ForConsumers\/ConsumerUpdates\/UCM258691.pdf>; 2012."},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0180","first-page":"1","volume":"26","author":"Milmo","year":"2013","journal-title":"BioPharm Int"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0185","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.yrtph.2012.08.009","article-title":"Nanoparticle iron medicinal products - requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies","volume":"64","author":"Borchard","year":"2012","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0190","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.yrtph.2010.09.021","article-title":"How to regulate nonbiological complex drugs (NBCD) and their follow-on versions: points to consider","volume":"59","author":"Schellekens","year":"2011","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0195","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4155\/bio.13.5","article-title":"Clinical development of biosimilars: an evolving landscape","volume":"5","author":"Subramanyam","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0200","unstructured":"FDA. <http:\/\/www.fda.gov\/downloads\/ScienceResearch\/SpecialTopics\/Nanotechnology\/ucm110856.pdf>; 2010."},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0205","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.it.2008.09.006","article-title":"New horizons in adjuvants for vaccine development","volume":"30","author":"Reed","year":"2009","journal-title":"Trends Immunol"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0210","unstructured":"WHO, WHO Expert Committee on Biological Standardisation. Guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines, http:\/\/www.who.int\/biologicals\/areas\/vaccines\/ADJUVANTS_Post_ECBS_edited_clean_Guidelines_NCE_Adjuvant_Final_17122013_WEB.pdf; 2013."},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0215","unstructured":"EMA, C. EMEA\/CHMP\/ VWP\/244894\/2006, <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003810.pdf>; 2006."},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0220","unstructured":"EMA, <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003875.pdf>; 2006."},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0225","unstructured":"FDA, <http:\/\/www.fda.gov\/downloads\/Adviso.uctsAdvisoryCommittee\/UCM181371.pdf>; 2009."},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0230","unstructured":"EMA, <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000550\/WC500021700.pdf>; 2005."},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0235","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0240","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fimmu.2014.00079","article-title":"TLR agonists as modulators of the innate immune response and their potential as agents against infectious disease","volume":"5","author":"Mifsud","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0245","unstructured":"EMA, <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003885.pdf>; 2002."},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0250","unstructured":"EMA, <http:\/\/vaccine-safety-training.org\/tl_files\/vs\/pdf\/EMEA.pdf>; 2005."},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0255","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijpharm.2012.04.047","article-title":"Vaccine delivery carriers: insights and future perspectives","volume":"440","author":"Correia-Pinto","year":"2013","journal-title":"Int J Pharm"},{"issue":"Suppl. 2","key":"10.1016\/B978-0-323-39981-4.00021-X_bib0260","doi-asserted-by":"crossref","first-page":"B14","DOI":"10.1016\/j.vaccine.2015.01.088","article-title":"New generation adjuvants-from empiricism to rational design","volume":"33","author":"O\u2019Hagan","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0265","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0264-410X(95)80005-X","article-title":"Adjuvant activity of QS-21 for experimental E. coli 018 polysaccharide vaccines","volume":"13","author":"Coughlin","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0270","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/0264-410X(94)90036-1","article-title":"Impact of the saponin adjuvant QS-21 and aluminium hydroxide on the immunogenicity of recombinant OspA and OspB of Borrelia burgdorferi","volume":"12","author":"Ma","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0275","doi-asserted-by":"crossref","first-page":"7016","DOI":"10.1016\/j.vaccine.2010.08.035","article-title":"Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three adjuvant systems","volume":"28","author":"Leroux-Roels","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0280","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1586\/14760584.7.8.1141","article-title":"Epaxal: a virosomal vaccine to prevent hepatitis A infection","volume":"7","author":"Bovier","year":"2008","journal-title":"Expert Rev Vaccin"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0285","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4161\/hv.22231","article-title":"Effectiveness of adjuvanted seasonal influenza vaccines (Inflexal V and Fluad) in preventing hospitalization for influenza and pneumonia in the elderly: a matched case-control study","volume":"9","author":"Gasparini","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0290","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/S0264-410X(98)00440-X","article-title":"Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs)","volume":"17","author":"Gl\u00fcck","year":"1999","journal-title":"Vaccine"},{"issue":"Suppl. 5","key":"10.1016\/B978-0-323-39981-4.00021-X_bib0295","doi-asserted-by":"crossref","first-page":"B10","DOI":"10.1016\/S0264-410X(02)00513-3","article-title":"New technology platforms in the development of vaccines for the future","volume":"20","author":"Gl\u00fcck","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0300","unstructured":"EMA, <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003857.pdf>; 2010."},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0305","unstructured":"EMA, <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/10\/WC500004004.pdf>; 1998."},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0310","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/10601333.2015.1001899","article-title":"EU regulatory guidelines for the clinical evaluation of adjuvants","volume":"32","author":"Klug","year":"2015","journal-title":"Clin Res Regul Aff"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0325","unstructured":"EMA, C. CPMP\/BWP\/477\/97, <http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl(pages\/regulation\/general\/general_content_000330.jsp&mid(WC0b01ac058002956b>; 1999."},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0330","unstructured":"EMA, <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/10\/WC500003987.pdf>; 2001."},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0335","unstructured":"EMA. EMEA\/CHMP\/SWP\/ 28367\/2007 Corr., <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002989.pdf>; 2007."},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0315","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1016\/j.vaccine.2004.11.072","article-title":"Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies","volume":"23","author":"Brennan","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0320","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.4161\/hv.23917","article-title":"Clinical evaluation of therapeutic cancer vaccines","volume":"9","author":"Ogi","year":"2013","journal-title":"Human Vaccin Immunother"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0340","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine","volume":"17","author":"Cheever","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0345","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2165\/11594010-000000000-00000","article-title":"Ipilimumab: first global approval.","volume":"71","author":"Cameron","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0350","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.addr.2009.06.003","article-title":"Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics.","volume":"61","author":"Gaspar","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0355","first-page":"717","volume":"58","author":"Bramwell","year":"2006","journal-title":"Particulate delivery systems for vaccines: what can we expect? J Pharm Pharmacol"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0360","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications.","volume":"161","author":"Danhier","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0365","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.smim.2011.01.001","article-title":"Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines.","volume":"23","author":"Tacken","year":"2011","journal-title":"Semin Immunol"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0370","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.2174\/138920012802850047","article-title":"Toxicological profile of therapeutic nanodelivery systems.","volume":"13","author":"Bimbo","year":"2012","journal-title":"Curr Drug Metab"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0375","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.biomaterials.2008.10.035","article-title":"The enhancement of the immune response against S. equi antigens through the intranasal administration of poly-epsilon-caprolactone-based nanoparticles.","volume":"30","author":"Florindo","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0380","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1517\/17425241003602259","article-title":"Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems.","volume":"7","author":"Fu","year":"2010","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0385","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.imlet.2011.06.002","article-title":"Comparative activity of biodegradable nanoparticles with aluminum adjuvants: Antigen uptake by dendritic cells and induction of immune response in mice.","volume":"140","author":"Uto","year":"2011","journal-title":"Immunol Lett"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0390","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.2217\/nnm.14.135","article-title":"Development of functionalized nanoparticles for vaccine delivery to dendritic cells: a mechanistic approach.","volume":"9","author":"Silva","year":"2014","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0395","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jconrel.2014.11.033","article-title":"In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model.","volume":"198","author":"Silva","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0400","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.0818-9641.2004.01271.x","article-title":"Vaccines that facilitate antigen entry into dendritic cells.","volume":"82","author":"Gamvrellis","year":"2004","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0405","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1016\/j.vaccine.2008.07.035","article-title":"Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity.","volume":"26","author":"Hamdy","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0410","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4161\/hv.4.1.4747","article-title":"Evidence based route of administration of vaccines.","volume":"4","author":"Cook","year":"2008","journal-title":"Hum Vaccin"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0415","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1158\/1078-0432.CCR-07-1441","article-title":"Therapeutic nanoparticles for drug delivery in cancer.","volume":"14","author":"Cho","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0420","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/eji.200737984","article-title":"Nanoparticles target distinct dendritic cell populations according to their size.","volume":"38","author":"Manolova","year":"2008","journal-title":"Eur J Immunol"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0425","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cell.2004.08.017","article-title":"Endocytosis by random initiation and stabilization of clathrin-coated pits.","volume":"118","author":"Ehrlich","year":"2004","journal-title":"Cell"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0430","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","article-title":"Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles.","volume":"307","author":"Owens","year":"2006","journal-title":"Int J Pharm"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0435","first-page":"1","volume":"40","author":"Xiang","year":"2006","journal-title":"Pathogen recognition and development of particulate vaccines: does size matter? Methods"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0440","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ijpharm.2005.03.035","article-title":"Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model.","volume":"298","author":"Foged","year":"2005","journal-title":"Int J Pharm"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0445","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s11671-007-9081-5","article-title":"Nanoparticles for applications in cellular imaging.","volume":"2","author":"Thurn","year":"2007","journal-title":"Nanoscale Res Lett"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0450","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1016\/j.biomaterials.2008.07.020","article-title":"Quantification of the force of nanoparticle-cell membrane interactions and its influence on intracellular trafficking of nanoparticles.","volume":"29","author":"Vasir","year":"2008","journal-title":"Biomaterials"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0455","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jconrel.2009.12.022","article-title":"Endocytic uptake of a large array of HPMA copolymers: Elucidation into the dependence on the physicochemical characteristics.","volume":"143","author":"Liu","year":"2010","journal-title":"J Control Release"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0460","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1021\/bm101482r","article-title":"Surface charge affects cellular uptake and intracellular trafficking of chitosan-based nanoparticles.","volume":"12","author":"Yue","year":"2011","journal-title":"Biomacromolecules"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/727241","article-title":"Targeted liposomal drug delivery to monocytes and macrophages.","volume":"2011","author":"Kelly","year":"2011","journal-title":"J Drug Deliv"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0470","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1126\/science.1137971","article-title":"Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation.","volume":"316","author":"Burgdorf","year":"2007","journal-title":"Science"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0475","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.coi.2007.12.002","article-title":"Endocytosis mechanisms and the cell biology of antigen presentation.","volume":"20","author":"Burgdorf","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0480","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1021\/bm060889x","article-title":"Conjugation of bioactive ligands to PEG-grafted chitosan at the distal end of PEG.","volume":"8","author":"Fernandez-Megia","year":"2007","journal-title":"Biomacromolecules"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0485","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jconrel.2009.09.005","article-title":"Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity.","volume":"141","author":"van den Berg","year":"2010","journal-title":"J Control Release"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0490","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nnano.2013.11","article-title":"Nanoparticles: pushed off target with proteins.","volume":"8","author":"Gaspar","year":"2013","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0495","doi-asserted-by":"crossref","first-page":"14265","DOI":"10.1073\/pnas.0805135105","article-title":"Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts.","volume":"105","author":"Lundqvist","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0500","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2217\/nnm.13.191","article-title":"Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles.","volume":"9","author":"Toy","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0505","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.addr.2011.06.016","article-title":"The effects of polymeric nanostructure shape on drug delivery.","volume":"63","author":"Venkataraman","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0510","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1021\/nl070363y","article-title":"Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes.","volume":"7","author":"Chithrani","year":"2007","journal-title":"Nano Lett"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0515","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s00204-011-0722-1","article-title":"Evaluation of the cytotoxic and inflammatory potential of differentially shaped zinc oxide nanoparticles.","volume":"85","author":"Heng","year":"2011","journal-title":"Arch Toxicol"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0520","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1007\/s00018-009-0053-z","article-title":"Nanocarriers\u2019 entry into the cell: relevance to drug delivery.","volume":"66","author":"Hillaireau","year":"2009","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0525","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nature08604","article-title":"Materials engineering for immunomodulation.","volume":"462","author":"Hubbell","year":"2009","journal-title":"Nature"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0530","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/S0006-3495(04)74265-4","article-title":"A statistical-thermodynamic model of viral budding.","volume":"86","author":"Tzlil","year":"2004","journal-title":"Biophys J"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0535","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1021\/nn9012274","article-title":"Size and dynamics of caveolae studied using nanoparticles in living endothelial cells.","volume":"3","author":"Wang","year":"2009","journal-title":"ACS Nano"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0540","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10544-011-9604-9","article-title":"Effect of size on the cellular endocytosis and controlled release of mesoporous silica nanoparticles for intracellular delivery.","volume":"14","author":"Gan","year":"2012","journal-title":"Biomed Microdevices"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0545","doi-asserted-by":"crossref","first-page":"9469","DOI":"10.1073\/pnas.0503879102","article-title":"From The Cover: Mechanics of receptor-mediated endocytosis.","volume":"102","author":"Gao","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/B978-0-323-39981-4.00021-X_bib0550","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.addr.2013.01.001","article-title":"Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: a concise overview.","volume":"65","author":"Mignani","year":"2013","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Micro and Nanotechnology in Vaccine Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B978032339981400021X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B978032339981400021X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T23:00:16Z","timestamp":1657407616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B978032339981400021X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9780323399814"],"references-count":109,"URL":"https:\/\/doi.org\/10.1016\/b978-0-323-39981-4.00021-x","relation":{},"subject":[],"published":{"date-parts":[[2017]]}}}